NM_024740.2:c.1538C>T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_024740.2(ALG9):​c.1538C>T​(p.Pro513Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00337 in 1,614,054 control chromosomes in the GnomAD database, including 18 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0020 ( 1 hom., cov: 33)
Exomes 𝑓: 0.0035 ( 17 hom. )

Consequence

ALG9
NM_024740.2 missense

Scores

2
6
11

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:11

Conservation

PhyloP100: 7.92

Publications

5 publications found
Variant links:
Genes affected
ALG9 (HGNC:15672): (ALG9 alpha-1,2-mannosyltransferase) This gene encodes an alpha-1,2-mannosyltransferase enzyme that functions in lipid-linked oligosaccharide assembly. Mutations in this gene result in congenital disorder of glycosylation type Il. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2008]
ALG9 Gene-Disease associations (from GenCC):
  • ALG9-associated autosomal dominant polycystic kidney disease
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • ALG9-congenital disorder of glycosylation
    Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P, PanelApp Australia, Orphanet
  • autosomal dominant polycystic kidney disease
    Inheritance: AD Classification: MODERATE, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet
  • Gillessen-Kaesbach-Nishimura syndrome
    Inheritance: AR Classification: MODERATE Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.008098453).
BP6
Variant 11-111836229-G-A is Benign according to our data. Variant chr11-111836229-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 166678.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.00203 (309/152286) while in subpopulation SAS AF = 0.00581 (28/4820). AF 95% confidence interval is 0.00413. There are 1 homozygotes in GnomAd4. There are 142 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAdExome4 at 17 AR,AD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ALG9NM_024740.2 linkc.1538C>T p.Pro513Leu missense_variant Exon 13 of 15 ENST00000616540.5 NP_079016.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ALG9ENST00000616540.5 linkc.1538C>T p.Pro513Leu missense_variant Exon 13 of 15 1 NM_024740.2 ENSP00000482437.1
ENSG00000258529ENST00000622211.4 linkc.2216C>T p.Pro739Leu missense_variant Exon 17 of 19 2 ENSP00000482396.1

Frequencies

GnomAD3 genomes
AF:
0.00203
AC:
309
AN:
152168
Hom.:
1
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000603
Gnomad AMI
AF:
0.00439
Gnomad AMR
AF:
0.00137
Gnomad ASJ
AF:
0.00202
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00580
Gnomad FIN
AF:
0.000661
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.00310
Gnomad OTH
AF:
0.00239
GnomAD2 exomes
AF:
0.00257
AC:
641
AN:
249506
AF XY:
0.00287
show subpopulations
Gnomad AFR exome
AF:
0.000581
Gnomad AMR exome
AF:
0.000811
Gnomad ASJ exome
AF:
0.00308
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000325
Gnomad NFE exome
AF:
0.00304
Gnomad OTH exome
AF:
0.00231
GnomAD4 exome
AF:
0.00351
AC:
5128
AN:
1461768
Hom.:
17
Cov.:
31
AF XY:
0.00363
AC XY:
2642
AN XY:
727190
show subpopulations
African (AFR)
AF:
0.000329
AC:
11
AN:
33472
American (AMR)
AF:
0.000827
AC:
37
AN:
44718
Ashkenazi Jewish (ASJ)
AF:
0.00299
AC:
78
AN:
26130
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39696
South Asian (SAS)
AF:
0.00677
AC:
584
AN:
86252
European-Finnish (FIN)
AF:
0.000505
AC:
27
AN:
53418
Middle Eastern (MID)
AF:
0.00538
AC:
31
AN:
5766
European-Non Finnish (NFE)
AF:
0.00374
AC:
4162
AN:
1111936
Other (OTH)
AF:
0.00328
AC:
198
AN:
60380
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.506
Heterozygous variant carriers
0
319
638
956
1275
1594
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
178
356
534
712
890
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00203
AC:
309
AN:
152286
Hom.:
1
Cov.:
33
AF XY:
0.00191
AC XY:
142
AN XY:
74448
show subpopulations
African (AFR)
AF:
0.000602
AC:
25
AN:
41560
American (AMR)
AF:
0.00137
AC:
21
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
0.00202
AC:
7
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5184
South Asian (SAS)
AF:
0.00581
AC:
28
AN:
4820
European-Finnish (FIN)
AF:
0.000661
AC:
7
AN:
10598
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.00310
AC:
211
AN:
68036
Other (OTH)
AF:
0.00236
AC:
5
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
19
38
56
75
94
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00265
Hom.:
2
Bravo
AF:
0.00190
TwinsUK
AF:
0.00485
AC:
18
ALSPAC
AF:
0.00493
AC:
19
ESP6500AA
AF:
0.000539
AC:
2
ESP6500EA
AF:
0.00196
AC:
16
ExAC
AF:
0.00267
AC:
323
Asia WGS
AF:
0.00318
AC:
11
AN:
3478
EpiCase
AF:
0.00344
EpiControl
AF:
0.00415

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:5
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Apr 26, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Mar 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ALG9: BS2 -

not specified Benign:3
Mar 10, 2014
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 04, 2024
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 13, 2022
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Gillessen-Kaesbach-Nishimura syndrome;C2931006:ALG9 congenital disorder of glycosylation Benign:1
Dec 07, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

ALG9 congenital disorder of glycosylation Benign:1
Jan 28, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

ALG9-related disorder Benign:1
Jun 01, 2020
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.085
BayesDel_addAF
Benign
-0.30
T
BayesDel_noAF
Benign
-0.20
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.43
T;.;.;.;.
Eigen
Benign
0.12
Eigen_PC
Uncertain
0.29
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.94
D;D;D;D;D
M_CAP
Benign
0.034
D
MetaRNN
Benign
0.0081
T;T;T;T;T
MetaSVM
Benign
-0.89
T
MutationAssessor
Uncertain
2.0
M;.;.;.;.
PhyloP100
7.9
PrimateAI
Uncertain
0.61
T
PROVEAN
Pathogenic
-5.0
.;D;D;.;.
REVEL
Benign
0.17
Sift
Benign
0.10
.;T;T;.;.
Sift4G
Benign
0.14
T;T;T;T;T
Polyphen
0.047
B;.;.;B;.
Vest4
0.61
MVP
0.79
MPC
0.43
ClinPred
0.039
T
GERP RS
5.2
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.29
gMVP
0.55
Mutation Taster
=80/20
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs185149177; hg19: chr11-111706952; COSMIC: COSV107503968; COSMIC: COSV107503968; API